NO985575D0 - FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese - Google Patents

FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese

Info

Publication number: NO985575D0
Authority: NO; Norway
Prior art keywords: beta; alpha; mediated angiogenesis; inhibiting; growth factor
Prior art date: 1996-05-31

Application number

NO985575A

Other languages

English (en)

Other versions

NO985575L (no

Inventor

Peter Brooks

David A Cheresh

Martin Friedlander

Original Assignee

Scripps Research Inst

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

1996-05-31

Filing date

1998-11-27

Publication date

1998-11-27

1998-11-27 Application filed by Scripps Research Inst filed Critical Scripps Research Inst

1998-11-27 Publication of NO985575D0 publication Critical patent/NO985575D0/no

1999-02-01 Publication of NO985575L publication Critical patent/NO985575L/no

Links

230000033115 angiogenesis Effects 0.000 title abstract 4
230000001404 mediated effect Effects 0.000 title abstract 3
230000002401 inhibitory effect Effects 0.000 title abstract 2
238000000034 method Methods 0.000 title abstract 2
238000002360 preparation method Methods 0.000 title 1
239000005557 antagonist Substances 0.000 abstract 2
NMWKYTGJWUAZPZ-WWHBDHEGSA-N (4S)-4-[[(4R,7S,10S,16S,19S,25S,28S,31R)-31-[[(2S)-2-[[(1R,6R,9S,12S,18S,21S,24S,27S,30S,33S,36S,39S,42R,47R,53S,56S,59S,62S,65S,68S,71S,76S,79S,85S)-47-[[(2S)-2-[[(2S)-4-amino-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-[[(2S)-2-amino-3-methylbutanoyl]amino]-3-methylbutanoyl]amino]-3-hydroxypropanoyl]amino]-3-(1H-imidazol-4-yl)propanoyl]amino]-3-phenylpropanoyl]amino]-4-oxobutanoyl]amino]-3-carboxypropanoyl]amino]-18-(4-aminobutyl)-27,68-bis(3-amino-3-oxopropyl)-36,71,76-tribenzyl-39-(3-carbamimidamidopropyl)-24-(2-carboxyethyl)-21,56-bis(carboxymethyl)-65,85-bis[(1R)-1-hydroxyethyl]-59-(hydroxymethyl)-62,79-bis(1H-imidazol-4-ylmethyl)-9-methyl-33-(2-methylpropyl)-8,11,17,20,23,26,29,32,35,38,41,48,54,57,60,63,66,69,72,74,77,80,83,86-tetracosaoxo-30-propan-2-yl-3,4,44,45-tetrathia-7,10,16,19,22,25,28,31,34,37,40,49,55,58,61,64,67,70,73,75,78,81,84,87-tetracosazatetracyclo[40.31.14.012,16.049,53]heptaoctacontane-6-carbonyl]amino]-3-methylbutanoyl]amino]-7-(3-carbamimidamidopropyl)-25-(hydroxymethyl)-19-[(4-hydroxyphenyl)methyl]-28-(1H-imidazol-4-ylmethyl)-10-methyl-6,9,12,15,18,21,24,27,30-nonaoxo-16-propan-2-yl-1,2-dithia-5,8,11,14,17,20,23,26,29-nonazacyclodotriacontane-4-carbonyl]amino]-5-[[(2S)-1-[[(2S)-1-[[(2S)-3-carboxy-1-[[(2S)-1-[[(2S)-1-[[(1S)-1-carboxyethyl]amino]-4-methyl-1-oxopentan-2-yl]amino]-4-methyl-1-oxopentan-2-yl]amino]-1-oxopropan-2-yl]amino]-1-oxopropan-2-yl]amino]-3-(1H-imidazol-4-yl)-1-oxopropan-2-yl]amino]-5-oxopentanoic acid Chemical compound CC(C)C[C@H](NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H]1CSSC[C@H](NC(=O)[C@@H](NC(=O)[C@@H]2CSSC[C@@H]3NC(=O)[C@H](Cc4ccccc4)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@@H](NC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@@H]4CCCN4C(=O)[C@H](CSSC[C@H](NC(=O)[C@@H](NC(=O)CNC(=O)[C@H](Cc4c[nH]cn4)NC(=O)[C@H](Cc4ccccc4)NC3=O)[C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](Cc3ccccc3)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCCN)C(=O)N3CCC[C@H]3C(=O)N[C@@H](C)C(=O)N2)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(N)=O)NC(=O)[C@H](Cc2ccccc2)NC(=O)[C@H](Cc2c[nH]cn2)NC(=O)[C@H](CO)NC(=O)[C@@H](NC(=O)[C@@H](N)C(C)C)C(C)C)[C@@H](C)O)C(C)C)C(=O)N[C@@H](Cc2c[nH]cn2)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](Cc2ccc(O)cc2)C(=O)N[C@@H](C(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N1)C(=O)N[C@@H](C)C(O)=O NMWKYTGJWUAZPZ-WWHBDHEGSA-N 0.000 abstract 1
108090000695 Cytokines Proteins 0.000 abstract 1
102000004127 Cytokines Human genes 0.000 abstract 1
102000009024 Epidermal Growth Factor Human genes 0.000 abstract 1
101800003838 Epidermal growth factor Proteins 0.000 abstract 1
102000006747 Transforming Growth Factor alpha Human genes 0.000 abstract 1
101800004564 Transforming growth factor alpha Proteins 0.000 abstract 1
108010073929 Vascular Endothelial Growth Factor A Proteins 0.000 abstract 1
102000005789 Vascular Endothelial Growth Factors Human genes 0.000 abstract 1
108010019530 Vascular Endothelial Growth Factors Proteins 0.000 abstract 1
102100035140 Vitronectin Human genes 0.000 abstract 1
108010031318 Vitronectin Proteins 0.000 abstract 1
230000002596 correlated effect Effects 0.000 abstract 1
201000010099 disease Diseases 0.000 abstract 1
208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
230000003511 endothelial effect Effects 0.000 abstract 1
229940116977 epidermal growth factor Drugs 0.000 abstract 1
230000004968 inflammatory condition Effects 0.000 abstract 1
230000005764 inhibitory process Effects 0.000 abstract 1
239000000203 mixture Substances 0.000 abstract 1
230000001225 therapeutic effect Effects 0.000 abstract 1
230000004614 tumor growth Effects 0.000 abstract 1
VBEQCZHXXJYVRD-GACYYNSASA-N uroanthelone Chemical compound C([C@@H](C(=O)N[C@H](C(=O)N[C@@H](CS)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CS)C(=O)N[C@H](C(=O)N[C@@H]([C@@H](C)CC)C(=O)NCC(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(O)=O)C(=O)N[C@@H](CC(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(O)=O)C(C)C)[C@@H](C)O)NC(=O)[C@H](CO)NC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CO)NC(=O)[C@H](CCC(O)=O)NC(=O)[C@@H](NC(=O)[C@H](CC=1NC=NC=1)NC(=O)[C@H](CCSC)NC(=O)[C@H](CS)NC(=O)[C@@H](NC(=O)CNC(=O)CNC(=O)[C@H](CC(N)=O)NC(=O)[C@H](CC(C)C)NC(=O)[C@H](CS)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)CNC(=O)[C@H](CC(O)=O)NC(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H]1N(CCC1)C(=O)[C@H](CS)NC(=O)CNC(=O)[C@H]1N(CCC1)C(=O)[C@H](CC=1C=CC(O)=CC=1)NC(=O)[C@H](CO)NC(=O)[C@@H](N)CC(N)=O)C(C)C)[C@@H](C)CC)C1=CC=C(O)C=C1 VBEQCZHXXJYVRD-GACYYNSASA-N 0.000 abstract 1
230000002792 vascular Effects 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
- C12N9/14—Hydrolases (3)
- C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
- C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
- C12N9/64—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue
- C12N9/6421—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from animal tissue from mammals
- C12N9/6489—Metalloendopeptidases (3.4.24)
- C12N9/6491—Matrix metalloproteases [MMP's], e.g. interstitial collagenase (3.4.24.7); Stromelysins (3.4.24.17; 3.2.1.22); Matrilysin (3.4.24.23)
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/43—Enzymes; Proenzymes; Derivatives thereof
- A61K38/46—Hydrolases (3)
- A61K38/48—Hydrolases (3) acting on peptide bonds (3.4)
- A61K38/4886—Metalloendopeptidases (3.4.24), e.g. collagenase
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/08—Antiallergic agents
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C279/00—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups
- C07C279/04—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton
- C07C279/14—Derivatives of guanidine, i.e. compounds containing the group, the singly-bound nitrogen atoms not being part of nitro or nitroso groups having nitrogen atoms of guanidine groups bound to acyclic carbon atoms of a carbon skeleton being further substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/02—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton
- C07C311/03—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms
- C07C311/06—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of an acyclic saturated carbon skeleton having the nitrogen atoms of the sulfonamide groups bound to hydrogen atoms or to acyclic carbon atoms to acyclic carbon atoms of hydrocarbon radicals substituted by carboxyl groups
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C311/00—Amides of sulfonic acids, i.e. compounds having singly-bound oxygen atoms of sulfo groups replaced by nitrogen atoms, not being part of nitro or nitroso groups
- C07C311/01—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms
- C07C311/10—Sulfonamides having sulfur atoms of sulfonamide groups bound to acyclic carbon atoms of a saturated carbon skeleton containing rings
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
- C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
- C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
- C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D263/36—One oxygen atom
- C07D263/38—One oxygen atom attached in position 2
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/745—Blood coagulation or fibrinolysis factors
- C07K14/75—Fibrinogen
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2839—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
- C07K16/2848—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta3-subunit-containing molecules, e.g. CD41, CD51, CD61
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/36—Systems containing two condensed rings the rings having more than two atoms in common
- C07C2602/42—Systems containing two condensed rings the rings having more than two atoms in common the bicyclo ring system containing seven carbon atoms

Landscapes

Health & Medical Sciences (AREA)
Chemical & Material Sciences (AREA)
Organic Chemistry (AREA)
Life Sciences & Earth Sciences (AREA)
General Health & Medical Sciences (AREA)
Medicinal Chemistry (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Veterinary Medicine (AREA)
Public Health (AREA)
Animal Behavior & Ethology (AREA)
Pharmacology & Pharmacy (AREA)
Immunology (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
General Chemical & Material Sciences (AREA)
Chemical Kinetics & Catalysis (AREA)
Proteomics, Peptides & Aminoacids (AREA)
Genetics & Genomics (AREA)
Gastroenterology & Hepatology (AREA)
Molecular Biology (AREA)
Biochemistry (AREA)
Epidemiology (AREA)
Biophysics (AREA)
Zoology (AREA)
Biomedical Technology (AREA)
Rheumatology (AREA)
Wood Science & Technology (AREA)
Hematology (AREA)
Diabetes (AREA)
Microbiology (AREA)
Pain & Pain Management (AREA)
Pulmonology (AREA)
Toxicology (AREA)
Physical Education & Sports Medicine (AREA)
Biotechnology (AREA)
Ophthalmology & Optometry (AREA)
Orthopedic Medicine & Surgery (AREA)
General Engineering & Computer Science (AREA)
Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)

NO985575A 1996-05-31 1998-11-27 FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese NO985575L (no)

Applications Claiming Priority (3)

Application Number	Priority Date	Filing Date	Title
US1586996P	1996-05-31	1996-05-31
US1873396P	1996-05-31	1996-05-31
PCT/US1997/009099 WO1997045447A1 (en)	1996-05-31	1997-05-30	METHODS AND COMPOSITIONS USEFUL FOR INHIBITION OF αvβ5 MEDIATED ANGIOGENESIS

Publications (2)

Publication Number	Publication Date
NO985575D0 true NO985575D0 (no)	1998-11-27
NO985575L NO985575L (no)	1999-02-01

Family

ID=26687899

Family Applications (2)

Application Number	Title	Priority Date	Filing Date
NO985574A NO985574L (no)	1996-05-31	1998-11-27	FremgangsmÕter og preparater anvendelige for inhibering av angiogenese
NO985575A NO985575L (no)	1996-05-31	1998-11-27	FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese

Family Applications Before (1)

Application Number	Title	Priority Date	Filing Date
NO985574A NO985574L (no)	1996-05-31	1998-11-27	FremgangsmÕter og preparater anvendelige for inhibering av angiogenese

Country Status (14)

Country	Link
EP (2)	EP0907661A4 (no)
JP (1)	JP2002515036A (no)
KR (2)	KR20000016301A (no)
CN (1)	CN1226254A (no)
AT (1)	ATE470450T1 (no)
BR (1)	BR9709514A (no)
CA (2)	CA2256588A1 (no)
CZ (2)	CZ380098A3 (no)
DE (1)	DE69739907D1 (no)
DK (1)	DK0951295T3 (no)
HU (2)	HUP9902099A3 (no)
NO (2)	NO985574L (no)
PL (2)	PL330241A1 (no)
WO (2)	WO1997045447A1 (no)

Families Citing this family (35)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US20040063790A1 (en) *	1996-05-31	2004-04-01	The Scripps Research Institute	Methods for inhibition of angiogenesis
US7387779B2 (en)	1998-06-17	2008-06-17	Beth Israel Deaconess Medical Center	Anti-angiogenic proteins and fragments and methods of use thereof
US6962974B1 (en)	1998-06-17	2005-11-08	Beth Israel Deaconess Medical Center	Anti-angiogenic proteins and fragments and methods of use thereof
US6759047B1 (en)	1998-06-17	2004-07-06	Beth Israel Deaconess Hospital Corp.	Anti-angiogenic proteins and methods of use thereof
AU740781B2 (en)	1998-07-14	2001-11-15	Pharmacia & Upjohn Company	Oxazolidinones to treat eye infections
DE19842415A1 (de) *	1998-09-16	2000-03-23	Merck Patent Gmbh	Pharmazeutische Zubereitung
US6521593B1 (en) *	1999-02-01	2003-02-18	Childrens Hospital Los Angeles	Methods for inhibiting brain tumor growth
US6344484B1 (en)	1999-02-12	2002-02-05	3-Dimensional Pharmaceuticals, Inc.	Tyrosine alkoxyguanidines as integrin inhibitors
PT1156823E (pt)	1999-02-12	2009-01-08	Scripps Research Inst	Métodos para tratamento de tumores e metástases utilizando uma combinação de terapias anti-angiogénicas e imunitárias
UA71608C2 (en) *	1999-03-11	2004-12-15	Merck Patent Gmbh	A method for producing the cyclic pentapeptide
JP2003534558A (ja) *	2000-05-26	2003-11-18	グラクソグループリミテッド	ＬＡＰ（潜在型結合ペプチド）とインテグリンαｖβ３との間の相互作用のモジュレーターを同定する方法及びその医学的使用
CN1329167A (zh) *	2000-06-19	2002-01-02	上海博德基因开发有限公司	一种新的多肽——人非整合蛋白－金属蛋白酶10.67和编码这种多肽的多核苷酸
US6486174B2 (en)	2000-08-07	2002-11-26	3-Dimensional Pharmaceuticals, Inc.	Tetrahydroisoquinoline-3-carboxylic acid alkoxyguanidines as integrin antagonists
ATE415163T1 (de)	2000-11-01	2008-12-15	Merck Patent Gmbh	Verfahren und zusammensetzungen zur behandlung von augenerkrankungen
MXPA03006772A (es)	2001-01-29	2004-10-15	Dimensional Pharm Inc	Indoles sustituidos y su uso como antogonistas de integrina.
WO2002085405A2 (en)	2001-04-24	2002-10-31	Merck Patent Gmbh	COMBINATION THERAPY USING ANTI-ANGIOGENIC AGENTS AND TNF$g(a)
US6872730B2 (en)	2001-04-27	2005-03-29	3-Dimensional Pharmaceuticals, Inc.	Substituted benzofurans and benzothiophenes, methods of making and methods of use as integrin antagonists
US7019108B2 (en) *	2001-06-01	2006-03-28	University Of Southern California	Method and composition for inhibition of angiogenesis and tumor growth using compounds based on a sequence within MMP-2
KR20040028966A (ko) *	2001-08-01	2004-04-03	메르크 파텐트 게엠베하	안구 질환 치료용 인테그린 억제제
DE10159453A1 (de) *	2001-12-04	2003-06-18	Merck Patent Gmbh	Verwendung von 1-Phenyl-oxazolidin-2-on-Verbindungen als Protease
GB0217017D0 (en) *	2002-07-23	2002-08-28	Bioacta Ltd	Peptide 2
FR2856598B1 (fr)	2003-06-25	2005-10-28	Inst Nat Sante Rech Med	Peptides derives de la proteine mmp-2 et leur utilisation en immunotherapie antitumorale
US7196061B2 (en) *	2003-09-10	2007-03-27	Wyeth	Compounds that modulate neuronal growth and their uses
WO2007084670A2 (en)	2006-01-18	2007-07-26	Merck Patent Gmbh	Specific therapy using integrin ligands for treating cancer
EP1862541A1 (en) *	2006-06-01	2007-12-05	Institut National De La Sante Et De La Recherche Medicale (Inserm)	Polypeptides derived from the hemopexin-like domain of metalloproteinase MMP-2
PL2101805T3 (pl)	2007-01-18	2013-04-30	Merck Patent Gmbh	Ligandy integryn do stosowania w leczeniu nowotworów
US20110243927A1 (en) *	2007-08-24	2011-10-06	University Health Network	Methods of inhibiting tumor growth using beta 5 integrin antagonists
EP2990487A1 (en)	2008-05-08	2016-03-02	Asuragen, INC.	Compositions and methods related to mirna modulation of neovascularization or angiogenesis
SG176103A1 (en)	2009-05-25	2011-12-29	Merck Patent Gmbh	Continuous administration of cilengitide in cancer treatments
KR101988362B1 (ko) *	2009-11-10	2019-06-12	알레그로 파마슈티칼스, 인코포레이티드.	Ｒｇｄ 바인딩 부위에 대한 세포 부착의 저해 또는 진단제 또는 치료제의 유도를 위한 조성물 및 방법
US11673914B2 (en)	2009-11-10	2023-06-13	Allegro Pharmaceuticals, LLC	Peptide therapies for reduction of macular thickening
WO2014163156A1 (ja)	2013-04-04	2014-10-09	味の素株式会社	脱保護方法
US20170362324A1 (en) *	2014-09-12	2017-12-21	Biogen Ma Inc.	Humanized anti-alpha v beta 5 antibodies and uses thereof
CN111748041B (zh) *	2019-03-11	2021-09-14	中国科学院苏州纳米技术与纳米仿生研究所	微环境控释型功能化水凝胶、其制备方法及应用
CN116239704B (zh) *	2023-05-09	2023-07-14	北京青云智创科技有限公司	一种治疗新生血管性眼病的多肽及其制剂

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US5770565A (en) *	1994-04-13	1998-06-23	La Jolla Cancer Research Center	Peptides for reducing or inhibiting bone resorption
CA2754102C (en) *	1995-08-14	2012-12-18	The Scripps Research Institute	Monoclonal antibodies and compositions comprising such useful for inhibition of .alpha.v.beta.5 mediated angiogenesis
DE19534177A1 (de) *	1995-09-15	1997-03-20	Merck Patent Gmbh	Cyclische Adhäsionsinhibitoren
DE19538741A1 (de) *	1995-10-18	1997-04-24	Merck Patent Gmbh	Cyclopeptidderivate

1997
- 1997-05-30 PL PL97330241A patent/PL330241A1/xx unknown
- 1997-05-30 HU HU9902099A patent/HUP9902099A3/hu unknown
- 1997-05-30 JP JP54291497A patent/JP2002515036A/ja not_active Abandoned
- 1997-05-30 CZ CZ983800A patent/CZ380098A3/cs unknown
- 1997-05-30 CA CA002256588A patent/CA2256588A1/en not_active Abandoned
- 1997-05-30 DE DE69739907T patent/DE69739907D1/de not_active Expired - Lifetime
- 1997-05-30 CA CA2256543A patent/CA2256543C/en not_active Expired - Fee Related
- 1997-05-30 CZ CZ983834A patent/CZ383498A3/cs unknown
- 1997-05-30 PL PL97330240A patent/PL330240A1/xx unknown
- 1997-05-30 WO PCT/US1997/009099 patent/WO1997045447A1/en not_active Application Discontinuation
- 1997-05-30 DK DK97928698.6T patent/DK0951295T3/da active
- 1997-05-30 CN CN97196818A patent/CN1226254A/zh active Pending
- 1997-05-30 WO PCT/US1997/009158 patent/WO1997045137A1/en not_active Application Discontinuation
- 1997-05-30 AT AT97928698T patent/ATE470450T1/de active
- 1997-05-30 EP EP97927814A patent/EP0907661A4/en not_active Withdrawn
- 1997-05-30 BR BR9709514A patent/BR9709514A/pt not_active IP Right Cessation
- 1997-05-30 HU HU9901628A patent/HUP9901628A3/hu unknown
- 1997-05-30 EP EP97928698A patent/EP0951295B1/en not_active Expired - Lifetime
- 1997-05-30 KR KR1019980709874A patent/KR20000016301A/ko not_active Application Discontinuation
- 1997-05-30 KR KR1019980709875A patent/KR20000016302A/ko not_active Application Discontinuation
1998
- 1998-11-27 NO NO985574A patent/NO985574L/no not_active Application Discontinuation
- 1998-11-27 NO NO985575A patent/NO985575L/no not_active Application Discontinuation

Also Published As

Publication number	Publication date
CA2256588A1 (en)	1997-12-04
KR20000016301A (ko)	2000-03-25
KR20000016302A (ko)	2000-03-25
NO985574L (no)	1999-02-01
WO1997045137A8 (en)	2001-02-01
DK0951295T3 (da)	2010-09-13
PL330241A1 (en)	1999-05-10
WO1997045447A1 (en)	1997-12-04
CZ380098A3 (cs)	1999-05-12
DE69739907D1 (de)	2010-07-22
HUP9902099A3 (en)	2001-10-29
PL330240A1 (en)	1999-05-10
EP0907661A1 (en)	1999-04-14
CA2256543C (en)	2010-12-07
CZ383498A3 (cs)	1999-05-12
HUP9901628A3 (en)	2002-11-28
WO1997045137A1 (en)	1997-12-04
CN1226254A (zh)	1999-08-18
BR9709514A (pt)	1999-08-10
ATE470450T1 (de)	2010-06-15
NO985575L (no)	1999-02-01
EP0907661A4 (en)	2000-07-26
HUP9902099A2 (hu)	1999-09-28
EP0951295A4 (en)	2000-07-26
JP2002515036A (ja)	2002-05-21
EP0951295A1 (en)	1999-10-27
HUP9901628A2 (hu)	1999-08-30
CA2256543A1 (en)	1997-12-04
EP0951295B1 (en)	2010-06-09
NO985574D0 (no)	1998-11-27

Publication	Publication Date	Title
NO985575D0 (no)	1998-11-27	FremgangsmÕter og preparater anvendelige for inhibering av <alfa>v<beta>5-mediert angiogenese
NO980622D0 (no)	1998-02-13	Fremgangsmåte og preparater anvendelige for inhibering av <alfa>v<beta>5-formidlet angiogenese
MX9604145A (es)	1998-05-31	Metodos y composiciones utiles para la inhibicion de angiogenesis.
EP0752987A4 (en)	1997-04-09	PYRIMIDINE DERIVATIVES AS INTERLEUKIN INHIBITORS
MY119778A (en)	2005-07-29	Androstenone derivative.
IL119461A (en)	2000-02-29	4,7-disubstituted -7H-pyrrolo ¬2, 3-d¾pyrimidines
NZ251320A (en)	1999-08-30	Bis-aromatic alpha,beta-unsaturated ketones, preparation and use in pharmaceutical compositions
DE69723863D1 (de)	2003-09-04	Chinoline und deren therapeutische verwendung
TR199802060T2 (xx)	1999-01-18	Aminoisokinolinler ve aminopiridin t�revlerinin iltihap �nleyiciler olarak kullan�m�.
DE69333931D1 (de)	2006-01-12	Verwendung von Krillenzymen zur Behandlung von Zahnbelag
ES2075845T3 (es)	1995-10-16	3,5-di-terc-butil-4-hidroxifenil-1,3,4-tiadiazoles, oxadiazoles y 3,5-di-terc-butil-4-hidroxifenil-1,2,4-tiadiazoles, oxadiazoles y triazoles como agentes antiinflamatorios.
ATE389655T1 (de)	2008-04-15	Pyrimidinderivate
ATE254472T1 (de)	2003-12-15	Hemmstoff für die gefässneubildung, der den gewebefaktor-inhibitor (tfpi) enthält
IT1271567B (it)	1997-05-30	Procedimento per l'ulteriore trattamento di salcicce
IT1251497B (it)	1995-05-15	Uso di 1,2 dipalmitoil-l-alfa-fosfatidil-n,n-dimetiletanolammina, in composizioni dermatologiche
DE69121210D1 (de)	1996-09-05	Therapeutische verwendung des fibroblastenwachstumsfaktors
TR200103748T2 (tr)	2002-05-21	Organ nakli reddinin inhibe edilmesi için UK 114 proteinin kullanımı
MA23755A1 (fr)	1996-07-01	Cyclohexanes-1-ols disubstitues en 4,4 monomeres et composes similaires
IT218963Z2 (it)	1992-11-12	Struttura di muretto artificiale, opportunamente attrezzato, particolarmente per l'arredamento di giardini, parchi e terrazzi
DE69133542D1 (de)	2006-09-28	Katheter zur Behandlung von Prostaterkrankungen
IT229299Y1 (it)	1998-07-02	Perfezionamento alla piegatura del maschietto per l'ancoraggio delle protesi dentarie
ITPN980034U4 (it)	1996-08-09	Sistema di aspirazione che permette di mantenere inalterato il buon odore nei bagni o toilette durante e dopo l'uso del vaso

Legal Events

Date	Code	Title	Description
2003-01-27	FC2A	Withdrawal, rejection or dismissal of laid open patent application